AbbVie Acquires Apogee Therapeutics for $10.9 Billion in Cash
AbbVie Inc. (ABBV) entered a merger agreement on June 22, 2026, to acquire Apogee Therapeutics, Inc. (APGE), in a deal valued at $10.9 billion. Deal Structure: AbbVie will acquire…
Written byAsif SuriaSource: InsideArbitrage
AbbVie Inc. (ABBV) entered a merger agreement on June 22, 2026, to acquire Apogee Therapeutics, Inc. (APGE), in a deal valued at $10.9 billion. Deal Structure: AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash, representing a 49.49% premium from the stock’s last close. Company Profile: Apogee Therapeutics is a